Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.

Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K.

Intern Med. 2017 Nov 15;56(22):2993-3001. doi: 10.2169/internalmedicine.9033-17. Epub 2017 Sep 25.

2.

Performance of Disease-Specific Scoring Models in Intensive Care Patients with Severe Liver Diseases.

El-Ghannam MT, Hassanien MH, El-Talkawy MD, Saleem AAA, Sabry AI, Abu Taleb HM.

J Clin Diagn Res. 2017 Jun;11(6):OC12-OC16. doi: 10.7860/JCDR/2017/24543.9980. Epub 2017 Jun 1.

3.

Ascites, refractory ascites and hyponatremia in cirrhosis.

Fortune B, Cardenas A.

Gastroenterol Rep (Oxf). 2017 May;5(2):104-112. doi: 10.1093/gastro/gox010. Epub 2017 Apr 24.

4.

Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia: A Meta-Analysis.

Zhang X, Zhao M, Du W, Zu D, Sun Y, Xiang R, Yang J.

Medicine (Baltimore). 2016 Apr;95(15):e3310. doi: 10.1097/MD.0000000000003310. Review.

5.

Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?

Fukui H.

World J Gastroenterol. 2015 Nov 7;21(41):11584-96. doi: 10.3748/wjg.v21.i41.11584. Review.

6.

Review of Tolvaptan's Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions.

Bhatt PR, McNeely EB, Lin TE, Adams KF, Patterson JH.

J Clin Med. 2014 Nov 12;3(4):1276-90. doi: 10.3390/jcm3041276. Review.

7.

Hyponatremia in Patients with Cirrhosis of the Liver.

Bernardi M, Ricci CS, Santi L.

J Clin Med. 2014 Dec 31;4(1):85-101. doi: 10.3390/jcm4010085. Review.

8.

The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.

Yan L, Xie F, Lu J, Ni Q, Shi C, Tang C, Yang J.

BMC Gastroenterol. 2015 Jun 9;15:65. doi: 10.1186/s12876-015-0297-z.

9.

Hyponatremia in cirrhosis: pathophysiology and management.

John S, Thuluvath PJ.

World J Gastroenterol. 2015 Mar 21;21(11):3197-205. doi: 10.3748/wjg.v21.i11.3197. Review.

10.

Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis.

Facciorusso A, Amoruso A, Neve V, Antonino M, Prete VD, Barone M.

World J Hepatol. 2014 Nov 27;6(11):793-9. doi: 10.4254/wjh.v6.i11.793. Review.

11.

Hyponatraemia and cirrhosis.

Gianotti RJ, Cardenas A.

Gastroenterol Rep (Oxf). 2014 Feb;2(1):21-6. doi: 10.1093/gastro/got037. Epub 2014 Jan 21.

12.

Management of hyponatremia.

Lee JJ, Kilonzo K, Nistico A, Yeates K.

CMAJ. 2014 May 13;186(8):E281-6. doi: 10.1503/cmaj.120887. Epub 2013 Dec 16. Review. No abstract available.

13.

Child-Na score: a predictive model for survival in cirrhotic patients with symptomatic portal hypertension treated with TIPS.

Chen H, Bai M, Qi X, Liu L, He C, Yin Z, Fan D, Han G.

PLoS One. 2013 Nov 11;8(11):e79637. doi: 10.1371/journal.pone.0079637. eCollection 2013.

14.

Vaptans and hyponatremia in critical patients.

D'Auria D, Marinosci GZ, De Benedictis G, Piazza O.

Transl Med UniSa. 2012 Apr 30;3:1-14. Print 2012 May.

15.

Vaptans: A new option in the management of hyponatremia.

Aditya S, Rattan A.

Int J Appl Basic Med Res. 2012 Jul;2(2):77-83. doi: 10.4103/2229-516X.106347.

16.

Cirrhotic ascites review: Pathophysiology, diagnosis and management.

Moore CM, Van Thiel DH.

World J Hepatol. 2013 May 27;5(5):251-63. doi: 10.4254/wjh.v5.i5.251.

17.

Improving survival in decompensated cirrhosis.

Mukerji AN, Patel V, Jain A.

Int J Hepatol. 2012;2012:318627. doi: 10.1155/2012/318627. Epub 2012 Jul 2.

18.

Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.

Gaglio P, Marfo K, Chiodo J 3rd.

Dig Dis Sci. 2012 Nov;57(11):2774-85. doi: 10.1007/s10620-012-2276-3. Epub 2012 Jun 26. Review.

19.

Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

Habib S, Boyer TD.

Therap Adv Gastroenterol. 2012 May;5(3):189-97. doi: 10.1177/1756283X12437357.

20.

Renal dysfunction in patients with chronic liver disease.

Lee JW.

Electrolyte Blood Press. 2009 Dec;7(2):42-50. doi: 10.5049/EBP.2009.7.2.42. Epub 2009 Dec 31.

Supplemental Content

Support Center